Skin / Melanoma Chemotherapy Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference.  Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie

Skin/Melanoma Chemotherapy Regimens

Regimen Name Indication

Cobimetinib and Vemurafenib Therapy

Regimen

00373a

Cobimetinib in combination with vemurafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Avelumab Monotherapy

Regimen

00535a

Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease

Dabrafenib Monotherapy

Regimen

00237a

Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Dacarbazine Therapy

Regimen

00464a

Treatment of metastatic malignant melanoma.

Encorafenib and Binimetinib Therapy

Regimen

00563a

Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation

Ipilimumab monotherapy

Regimen

00105a

Treatment of adults with advanced (unresectable or metastatic) malignant melanoma.

Nivolumab 240mg Monotherapy

Regimen

00483a

As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Nivolumab 480mg Monotherapy

Regimen

00484a

As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.

Nivolumab 3mg/kg Monotherapy

Regimen

00573a

As monotherapy for the adjuvant treatment of adults with melanoma with
involvement of lymph nodes or metastatic disease who have undergone
complete resection

Nivolumab Ipilimumab Combination Therapy

Regimen

00431a

Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults

Pembrolizumab 200mg Monotherapy Regimen

Regimen

00455b (Previously 00347a)

As monotherapy for the treatment of adults with unresectable or advanced melanoma

00455c (Previously 00347b)

For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma.

Pembrolizumab 400 mg Monotherapy

Regimen

00558b

As monotherapy for the treatment of adults with unresectable or advanced melanoma

00558c

For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma

Trametinib and Dabrafenib Therapy

Regimen

00415a

Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Vismodegib Monotherapy

Regimen

00236a

Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)

00236b

Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.

Vemurafenib Monotherapy

Regimen

00102a

Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma